The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Long-Term Efficacy and Safety of Cyclosporine in Renal-Transplant Recipients
Open accessAbstract
BACKGROUND AND METHODS: The safety of long-term immunosuppression with cyclosporine in renal-transplant recipients is not well understood. This drug may cause a progressive toxic nephropathy, but it also preserves renal function because it prevents rejection. To determine the effect of cyclosporine on renal function and graft rejection, we conducted a retrospective analysis of data on 1663 renal-transplant recipients at six centers. RESULTS: The rate of graft survival was 78 percent (median follow-up, 36 months). Grafts were was lost in 279 patients (17 percent), mostly because of acute rejection (68 patients) or chronic graft dysfunction that was unresponsive to a reduction in the dose of cyclosporine (125 patients); 92 patients died with functioning grafts. The median change in the serum creatinine concentration in all patients after transplantation was less than 0.001 mg per deciliter per month (< 0.09 mumol per liter per month). Patients who had episodes of rejection had decreased rates of long-term graft function and survival. Eight percent of patients with functioning grafts at one year had first episodes of rejection more than one year after transplantation. These late first rejections were associated with noncompliance with therapy (in 34 percent), blood cyclosporine concentrations that were marginally lower than those of patients who had no episodes of rejection, and a low rate of successful reversal of rejection (77 percent, vs. 97 percent in patients with rejection during the first year; P < 0.001). CONCLUSIONS: The majority of renal-transplant patients tolerate long-term cyclosporine therapy without evidence of progressive toxic nephropathy. Graft failure is most often due to rejection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LRISK FACTORS FOR CHRONIC REJECTION IN RENAL ALLOGRAFT RECIPIENTS
ALMOND, P. S., MATAS, A., GILLINGHAM, K., DUNN, D. L., PAYNE, W. D., NAJARIAN, J. S., PAUL, G., & RAINER, G. (1993) · Transplantation · doi:10.1097/00007890-199304000-00013 · Cited by 660
The long-term course of cyclosporine-associated chronic nephropathy
Myers, B. D., Sibley, R., Newton, L., Tomlanovich, S. J., Boshkos, C., Stinson, E., Luetscher, J. A., Whitney, D. J., Krasny, D., Coplon, N. S., et al. (1988) · Kidney International · doi:10.1038/ki.1988.38 · Cited by 506
Risk Factors for Cyclosporine-Induced Nephropathy in Patients with Autoimmune Diseases
Feutren, G., & Mihatsch, M. J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199206183262502 · Cited by 405
EARLY VERSUS LATE ACUTE RENAL ALLOGRAFT REJECTION: IMPACT ON CHRONIC REJECTION
BASADONNA, G. P., MATAS, A. J., GILLINGHAM, K. J., PAYNE, W. D., DUNN, D. L., SUTHERLAND, D. E. R., GORES, P. F., GRUESSNER, R. W. G., & NAJARIAN, J. S. (1993) · Transplantation · doi:10.1097/00007890-199305000-00007 · Cited by 353
Cyclosporine: Five Years' Experience in Cadaveric Renal Transplantation
Merion, R. M., White, D. J. G., Thiru, S., Evans, D. B., & Calne, R. Y. (1984) · New England Journal of Medicine · doi:10.1056/nejm198401193100303 · Cited by 308
A Randomized Clinical Trial of Cyclosporine in Cadaveric Renal Transplantation
The Canadian Multicentre Transplant Study Group (1986) · New England Journal of Medicine · doi:10.1056/nejm198605083141904 · Cited by 296
CYCLOSPORIN IN CADAVERIC RENAL TRANSPLANTATION: ONE-YEAR FOLLOW-UP OF A MULTICENTRE TRIAL
European Multicentre Trial Group (1983) · The Lancet · doi:10.1016/s0140-6736(83)90978-9 · Cited by 232
GULANIKAR, A. C., MACDONALD, A. S., SUNGURTEKIN, U., & BELITSKY, P. (1992) · Transplantation · doi:10.1097/00007890-199202010-00013 · Cited by 187
Canafax, D. M., Min, D. I., Gruber, S. A., Matas, A. J., Payne, W. D., Dunn, D. L., Sutherland, D. E. R., Simmons, R. L., Najarian, J. S., & Fryd, D. S. (1989) · Clinical Transplantation · doi:10.1111/j.1399-0012.1989.tb00546.x · Cited by 19
Cited by
Dantal, J., Hourmant, M., Cantarovich, D., Giral, M., Blancho, G., Dreno, B., & Soulillou, J.-P. (1998) · The Lancet · doi:10.1016/s0140-6736(97)08496-1 · Cited by 745
Flechner, S. M., Goldfarb, D., Modlin, C., Feng, J., Krishnamurthi, V., Mastroianni, B., Savas, K., Cook, D. J., & Novick, A. C. (2002) · Transplantation · doi:10.1097/00007890-200210270-00002 · Cited by 375
Melatonin ameliorates the drug induced nephrotoxicity: Molecular insights
Raza, Z., & Naureen, Z. (2020) · Nefrología · doi:10.1016/j.nefro.2019.06.009 · Cited by 43
Flippin, M. S., Canter, C. E., & Balzer, D. T. (2000) · The Journal of Heart and Lung Transplantation · doi:10.1016/s1053-2498(00)00061-9 · Cited by 31
Metadata
- Authors
- Burke, J. F., Pirsch, J. D., Ramos, E. L., Salomon, D. R., Stablein, D. M., Van Buren, D. H., & West, J. C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1994-08-11
- Volume
- 331
- Issue
- 6
- Pages
- 358-363
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2319735235
- Cited by
- 264
- References
- 9
- FWCI
- 18.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-Term Efficacy and Safety of Cyclosporine in Renal-Transplant Recipients. https://app.cochat.ai/papers/10.1056/nejm199408113310604
- The paper
- Burke, J. F., Pirsch, J. D., Ramos, E. L., Salomon, D. R., Stablein, D. M., Van Buren, D. H., & West, J. C. (1994). Long-Term Efficacy and Safety of Cyclosporine in Renal-Transplant Recipients. New England Journal of Medicine. https://doi.org/10.1056/nejm199408113310604
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
